AUA 2019: Experts outline the must-see presentations in Chicago

In advance of this year’s AUA annual meeting, Urology Times asked members of our editorial board to choose the top presentations-instructional courses (IC), plenary sessions, forums, and video sessions (V), among others-in their subspecialty. They also commented on what’s hot and, in some cases what’s not, in their area of interest. Click on any topic below to see the board’s abstract picks for that category. Urolithiasis/Endourology Prostate Cancer Kidney, Bladder, and Urothelial Cancer/Localized Prostate Cancer Sexual Function/Dysfunction Health Policy Trauma/Reconstruction/Diversion Infertility Voiding Dysfunction (male)/BPH Female Urology Pediatrics Late-breaking abstracts Quality and Patient Safety Clinical Epidemiology OAB/Male Incontinence Urolithiasis/Endourology Brian R. Matlaga, MD, MPH Among the hot trends in stone disease: opioid use, high-power lasers, and single-use ureteroscopes. “Due to the pain that accompanies a kidney stone event, opioids are commonly utilized. The urologic community is beginning to recognize this as an opportunity to improve practice patterns by decreasing reliance on opioids,” said Dr. Matlaga, professor of urology at Johns Hopkins, Baltimore. A “dusting” approach to ureteroscopic laser lithotripsy has become increasingly popular, and among its purported benefits are shorter operative times and reduced complication rates. “We are now seeing increasing reports on the outcomes associated with this treatment approach, as well as better understanding of the physics of high-frequency laser lithotripsy,” Dr. Matlaga said. The market for single-use ureteroscopes has evolved, and there are now multiple device companies providing single-use devices. “Concomitantly, the urologic community is working to better understand how these devices fit into present practice environments,” he said. Dr. Matlaga's meeting picks: 031IC: Surgical & Medical Stone Guidelines Update: A Case-Based Approach 026IC: Dust or Bust: A Beginner’s Guide to Modern Day Laser Lithotripsy Strategies For Ureteroscopy 078IC: Catastrophies, Complications & Corrections of Percutaneous Stone Procedures 019IC: New Technology in the Management of Stone Disease: What’s New, What Works, & What to Buy 008IC: Advanced Ureteroscopy: Overcoming Challenging Problems PD01-05: HIGH POWER HOLMIM MOSES TECHNOLOGY VERSUS SUPER-PULSE THULIUM FIBRE LASER. WHICH IS MORE EFFICIENT ON STONES? MP17-02: URETERAL STRICTURE FORMATION AFTER USE OF URETERAL ACCESS SHEATH – 4 YEAR FOLLOW-UP DATA MP17-20: A COMPARISON OF PATIENT DESIRED OUTCOMES BETWEEN PAIN AND NON-PAIN-FOCUSED PATIENTS FOLLOWING NEPHROLITHIASIS SURGERY MP23-01: RATE OF OPIOID PRESCRIPTION REFILLING FOLLOWING UROLOGIC STONE SURGERY MP23-07: NATURAL HISTORY OF RESIDUAL FRAGMENTS AFTER URETEROSCOPY MP23-12: UNDERSTANDING URETERAL ACCESS SHEATH USE WITHIN A STATEWIDE COLLABORATIVE AND ITS EFFECTS ON SURGICAL OUTCOMES AND COMPLICATIONS MP23-18: A CLINICAL TRACKING PROGRAM FOR URETERAL STENTS INTEGRATED INTO EMR PD42-05: TEMPERATURE RISE DURING LASER LITHOTRIPSY: COMPARISON OF SUPER PULSE THULIUM FIBER LASER (SPTF) VS HIGH POWER 120W HOLMIUM-YAG LASER (HO:YAG) PD42-07: RISK FACTORS FOR SEPSIS FOLLOWING PERCUTANEOUS NEPHROLITHOTOMY IN THE UNITED KINGDOM MP79-19: COMPARISON OF DUSTING AND FRAGMENTING USING THE NEW SUPER PULSE THULIUM FIBER LASER TO A 120W HOLMIUM:YAG LASER Next:Prostate Cancer Prostate Cancer J. Brantley Thrasher, MD “Areas that are hot are covered by some of my choices, such as immunotherapy in many cancers-even prostate cancer,” said Dr. Thrasher, professor of urology at the University of Kansas, Kansas City. “Another area that continues to grow in prostate cancer is imaging and genetic markers-specifically their use in diagnosis and treatment planning. Continued advances in imaging, specifically PET scanning, have helped in the targeting of biochemically recurrent prostate cancer.” Active surveillance for low-risk prostate cancer has significantly grown in popularity. “It has been widely accepted by urologists, and the only real question left is the standardization of the approach. It’s probably the fastest growing part of my practice,” he said. Dr. Thrasher's meeting picks: 023IC: Chemotherapy and Immunotherapy Options for Genitourinary Malignancies: A Primer for Urologists and Advanced Practice Providers 024IC: Prostate Cancer Diagnostics: Biomarkers, MRI, & Biopsy Techniques 083IC: AUA Guideline 2019: Incontinence After Prostate Treatment 001IC: Active Surveillance for Prostate Cancer: 2019 Update Prostate Cancer Trends Over the Last Decade: Is the Disease Becoming More Advanced? Effect of the 2012 Task Force Recommendations (SocietÃ Italiana di Urologia lecture) Panel Discussion: Enhanced PET imaging for High Risk and Advanced Prostate Cancer: Ready for Prime Time? Panel Discussion: Biomarkers in Prostate Cancer Next:Kidney, Bladder, and Urothelial Cancer/Localized Prostate Cancer Kidney, Bladder, and Urothelial Cancer/Localized Prostate Cancer Leonard G. Gomella, MD “Nonmuscle-invasive bladder cancer is an area of intense interest due in part to the worldwide shortage of our gold-standard BCG,” said Dr. Gomella, professor and chairman of urology at Thomas Jefferson University, Philadelphia. “Newer intravesical agents are critically needed that may address the shortage. The concept that systemically administered immuno-oncology agents can impact nonmuscle-invasive bladder cancer is revolutionary and is being tested in a variety of clinical trials. In kidney cancer, Dr. Gomella said robot-assisted surgery for partial nephrectomy has entered the mainstream of surgical care, but the same cannot be said for muscle-invasive bladder cancer. “We continue to be conflicted concerning the risks and benefits of robotic surgery in the management of muscle-invasive bladder cancer compared to traditional open surgery,” he said. Dr. Gomella's meeting picks: 010IC: Renal Cell Carcinoma: Surgical & Medical Management of High-Risk Renal Cell Carcinoma: New Paradigms for Treatment 077IC: Integrating Care for Oncology Patients: Establishing a Multidisciplinary Oncology Clinic with Advanced Therapeutics Crowdsourcing: Transurethral Resection of Bladder Tumor 023IC: Chemotherapy and Immunotherapy Options for Genitourinary Malignancies: A Primer for Urologists and Advanced Practice Providers 072IC: Management of NMIBC: Practical Solutions for Common Problems Crossfire:Controversies in Urology: Cytoreductive Radical Therapy still has a Role in the Era of Targeted Therapy for Metastatic RCC PD40-11: THE ROLE OF 68GA-PSMA PET-CT IN INITIAL STAGING OF TREATMENT-NAÃ¯VE HIGH RISK PROSTATE CANCER. PD45-02: OPIOID USE BEFORE AND AFTER RADICAL PROSTATECTOMY: NATIONWIDE POPULATION-BASED STUDY MP66-01: APICAL INVOLVEMENT IS ASSOCIATED WITH ADVERSE PATHOLOGICAL OUTCOMES IN MEN WITH LOW RISK PROSTATE CANCER ELIGIBLE FOR ACTIVE SURVEILLANCE PD45-04: IMPROVING QUALITY OF PROSTATE CANCER SURGERY BY PROVIDING FEEDBACK TO SURGEONS: THE SURGICAL REPORT CARD (SUREP) STUDY PD45-12: DEVELOPMENT AND EXTERNAL VALIDATION OF A NOVEL RISK SCORE TO PREDICT LONG-TERM CLINICAL RECURRENCE AFTER RADICAL PROSTATECTOMY MP54-01: FACILITY-LEVEL VARIATION IN PELVIC LYMPH NODE DISSECTION DURING RADICAL PROSTATECTOMY AND EFFECT ON OVERALL SURVIVAL IN MEN WITH CLINICALLY LOCALIZED HIGH-RISK PROSTATE CANCER MP54-10: COMPARISON BETWEEN LIMITED AND EXTENDED LYMPH NODE DISSECTION FOR PROSTATE CANCER: RESULTS FROM A LARGE, CLINICALLY-INTEGRATED, RANDOMIZED TRIAL MP60-09: EFFECT OF EXTENDED PELVIC LYMPH NODE DISSECTION ON ONCOLOGIC OUTCOMES IN D’AMICO INTERMEDIATE- AND HIGH-RISK RADICAL PROSTATECTOMY PATIENTS MP54-18: IMPACT OF PELVIC LYMPH NODE YIELD DURING RADICAL PROSTATECTOMY ON LONG TERM CSS AND OS: A RETROSPECTIVE 5- AND 10-YEARS ANALYSIS ON A 1274 SERIES MP54-13: EVALUATING THE VALUE OF MRI IN PREDICTING RADICAL PROSTATECTOMY PATHOLOGIC OUTCOMES MP54-16: HIGHER FREE TESTOSTERONE PROTECTS AGAINST EARLY RECURRENCE IN MEN UNDERGOING RADICAL PROSTATECTOMY MP60-03: CLINICAL SIGNIFICANCE AND PREDICTORS OF ONCOLOGIC OUTCOME AFTER RADICAL PROSTATECTOMY FOR INVISIBLE PROSTATE CANCER ON MULTIPARAMETRIC MRI MP60-06: 90-DAY READMISSION AFTER RADICAL PROSTATECTOMY - A PROSPECTIVE COMPARISON BETWEEN ROBOT-ASSISTED AND OPEN SURGERY MP66-09: A CONTEMPORARY ANALYSIS OF TREATMENT SELECTION AND COMPARATIVE EFFICACY OF TREATMENT FOR MEN WITH DUCTAL CARCINOMA OF THE PROSTATE MP78-03: TUMOR CONTROL OUTCOMES OF SALVAGE CRYOTHERAPY FOR RADIORECURRENT PROSTATE CANCER AT MEDIAN 12 YEARS FOLLOW-UP MP78-07: DO CONTEMPORARY IMAGING AND BIOPSY TECHNIQUES RELIABLY IDENTIFY UNILATERAL PROSTATE CANCER? IMPLICATIONS FOR HEMIABLATION PATIENT SELECTION MP78-10: A COMPARISON OF CANCER CONTROL OUTCOMES AT 5 YEARS OF FOCAL THERAPY (USING HIFU & CRYOTHERAPY) TO RADICAL PROSTATECTOMY FOR CLINICALLY SIGNIFICANT NON-METASTATIC PROSTATE CANCER: PROPENSITY SCORE-MATCHED ANALYSIS Next:Sexual Function/Dysfunction Sexual Function/Dysfunction Key trends in sexual function/dysfunction include the emergence of men’s health clinics, new non-drug treatments for erectile dysfunction, new testosterone replacement guidelines, and management of female sexual dysfunction, said Dr. Burnett, professor of urology at Johns Hopkins, Baltimore. “Certainly as we continue to make strides in female sexual dysfunction and consider what approaches we may bring to those presenting with female sexual dysfunction problems, we need to be more versed in the area,” he said. Dr. Burnett was particularly enthusiastic about a panel discussion on novel therapies for ED and Peyronie’s disease. “I think it’s important that we do have a good discussion from experts highlighting what’s new but also help urologists be guided on what is proper therapy, what is effective therapy, what is therapy that they should know is likely to be of benefit to patients. This is all the more important in the past year or so with therapies that are getting a lot of attention, such as stem cell therapy and shock wave therapy, that at this time remain incompletely understood. “The other trend that I see is that urology practices are trying to not let some of their potential practice and revenue go out to [non-urologists]. They’re sensing that this is their source of revenue and their domain [and that] if we don’t do it, these other will do it, so we better do it.” Dr. Burnett's meeting picks: 043IC: How to Start, Build & Run A Successful Andrology/Men’s Health Practice 036IC: What the Urologist Needs to Know to Manage Female Sexual Dysfunction Panel Discussion: Novel Therapies for Erectile Dysfunction and Peyronie’s Disease Complex Cases: Androgens: Charting the Course through the sea of Guidelines V04: ED, Infertility & Transgender MP27-06: IMMEDIATE PREOPERATIVE BLOOD GLUCOSE AND HEMOGLOBIN A1C LEVELS ARE NOT PREDICTIVE OF POST-OPERATIVE INFECTIONS IN DIABETIC MEN UNDERGOING PENILE PROSTHESIS PLACEMENT MP40-07: THE PREDICTIVE EFFECT OF FREE TESTOSTERONE ON SEXUAL FUNCTION INCREASES WITH AGE MP40-09: RE-ENGINEERING THE INTERNATIONAL INDEX OF ERECTILE FUNCTION: EVALUATION OF A LARGE CLINICAL DATA SET MP58-06: ASSESSMENT OF ERYTHROCYTOSIS FOLLOWING LONG-ACTING TESTOSTERONE SUPPLEMENTATION MP58-10: BIOCHEMICAL RECURRENCE RATES IN MEN WITH HIGH GRADE PROSTATE CANCER ON TESTOSTERONE THERAPY MP65-18: PRELIMINARY OUTCOMES OF A NOVEL PENILE TRACTION DEVICE (RESTOREX) IN MEN WITH PEYRONIE’S DISEASE: A RANDOMIZED, CONTROLLED TRIAL PD44-02: A MULTI-INSTITUTIONAL ASSESSMENT OF MULTIMODAL ANALGESIA IN PENILE IMPLANT RECIPIENTS DEMONSTRATES DRAMATIC NARCOTICS REDUCTION PD44-09: ADHERENCE TO THE AUA ANTIBIOTIC PROPHYLAXIS GUIDELINES IN DIABETIC PATIENTS IS ASSOCIATED WITH SIGNIFICANTLY HIGHER RISKS OF PENILE PROSTHESIS INFECTION Next:Health Policy Health Policy Jeffrey E. Kaufman, MD “In general, the Practice Management Conference provides an up-to-date, cutting-edge, nuts-and-bolts summary of what practitioners need to know to successfully bill in 2019,” said Dr. Kaufman, who is in private practice in Santa Ana, CA. “If members attended one health policy course at the conference, this would be it. “The AUA has an agenda according to which we lobby and educate Congress and private payers on our patients’ behalf to get appropriate coverage. Understanding why we hold the opinions we do weaponizes individual urologists to argue locally or get involved in national advocacy. Every AUA member-in private practice, academia, or training-should attend.” Dr. Kaufman's meeting picks: 16th Annual AUA Urology Practice Management Conference (2-day event) AUA Public Policy Council Liaison Update Next:Trauma/Reconstruction/Diversion Trauma/Reconstruction/Diversion Bradley A. Erickson, MD, MS “The armamentarium of the reconstructive urologist continues to expand. Many centers around the country have begun to offer gender-affirming genital surgery for our transgender patients and this year’s AUA will offer a course, co-sponsored by the Genitourinary Reconstruction Society (GURS), on how to incorporate transgender care into your practice,” said Dr. Erickson, associate professor of urology at the University of Iowa, Iowa City. “Cancer survivorship continues to be a popular topic at the meeting, especially after the treatment of prostate cancer. We continue to get better at prolonging the life of genitourinary cancer patients; the focus now turns to how improve their quality of life after treatment. “The benefits of robot-assisted surgery for reconstruction of the urinary tract continue to be explored, with the ureter being the most obvious organ of benefit, but also in the management of post-prostatectomy anastomotic strictures,” Dr. Erickson said. Dr. Erickson's meeting picks: Forum: Gender-Affirming Genital Surgery 032IC: Management of Complicated Urinary Dysfunction after Prostate Cancer Treatment 002IC: Robotic Upper Urinary Tract Reconstruction: A Top to Bottom Approach MP04-03: TREATMENT COMPLICATIONS ASSOCIATED WITH EXTRAPERITONEAL BLADDER INJURIES: RESULTS FROM THE MULTI-INSTITUTIONAL AAST STUDY OF BLADDER TRAUMA MP61-12: AVOID THE DELAY? DOES IMMEDIATE URETERAL RECONSTRUCTION FOR IATROGENIC URETERAL INJURY JEOPARDIZE OUTCOME? MP04-13: SPERMATOGENESIS IN THE TRANSGENDER TESTIS MP04-17: GENDER-AFFIRMING VAGINECTOMY AND COLPOCLEISIS PD22-05: SURGICAL TREATMENT FOR RECURRENT BULBAR URETHRAL STRICTURE: A RANDOMISED OPEN LABEL SUPERIORITY TRIAL OF OPEN URETHROPLASTY VERSUS ENDOSCOPIC URETHROTOMY (THE OPEN TRIAL) PD22-09: NATIONAL TRENDS IN URETHRAL STRICTURE MANAGEMENT MP55-09: ENDOSCOPIC TREATMENTS PRIOR TO URETHROPLASTY: TRENDS IN MANAGEMENT OF URETHRAL STRICTURE DISEASE SINCE THE AUA GUIDELINE MP55-10: UTILIZATION OF ENDOSCOPIC MANAGEMENT FOR URETHRAL STRICTURES IN AQUA PD22-06: ONE-YEAR SAFETY AND EFFICACY OUTCOMES ON A NOVEL DRUG COATED BALLOON (DCB) FOR URETHRAL STRICTURE DISEASE - THE ROBUST I STUDY PD33-02: CONTEMPORARY MULTICENTER OUTCOMES COMPARING CUTANEOUS CATHETERIZABLE ILEOCECOCYSTOPLASTY TO ILEOCYSTOPLASTY WITH A TUNNELED CATHETERIZABLE CHANNEL IN THE ADULT POPULATION: A NEUROGENIC BLADDER RESEARCH GROUP (NBRG) STUDY PD33-05: MITROFANOFF CONTINENT URINARY DIVERSION : BETTER LIFE CONFORT IN SPITE OF SURGICAL COMPLICATIONS MP61-16: OUTCOMES OF URINARY DIVERSION CREATED FOR LATE ADVERSE EFFECTS OF GYNECOLOGIC RADIOTHERAPY MP55-01: PROTEIN EXPRESSION PROFILES AMONG LICHEN SCLEROSUS URETHRAL STRICTURES: CAN URETHROPLASTY SUCCESS BE PREDICTED? MP67-20: DIRECTED NON-ONCOLOGIC PATHOLOGY REVIEW IDENTIFIES A HIGH PREVALENCE OF CHRONIC INFLAMMATION WITHIN ANTERIOR URETHROPLASTY STRICTURE SPECIMENS Next:Infertility Infertility James M. Hotaling, MD, MS “Research examining surgical or medical outcomes in male infertility prospectively from multi-institution databases will continue to drive the field forward,” said Dr. Hotaling, assistant professor of surgery (urology) at the University of Utah, Salt Lake City. “Translational work that allows refinement of the male infertility phenotype through molecular diagnostics in order to provide personalized care will also be a key theme. Finally, work that begins to apply the tools of health services research to male infertility will also be featured.” What’s not hot? “Single-surgeon case series, work that further validates existing series in varicocele repair, and work that looks at the impact of single genes on male infertility is fading in importance,” Dr. Hotaling said. Dr. Hotaling's meeting picks: 049IC: Infertility Update 2019: A Comprehensive Approach to Understanding & Treating Male Infertility in the Era of IVF 069IC: Emerging Concepts in Hormone Replacement Therapy for Men and Women Crossfire: Controversies in Urology: Vasectomy Reversal should be done even if the Spouse is 42 years old PD29-01: ONLY HIGH-RISK HUMAN PAPILLOMAVIRUS IN SEMEN IS ASSOCIATED WITH HIGH SPERM DNA FRAGMENTATION INDEX IN PRIMARY INFERTILE MEN PD29-04: QUALITATIVE ASSESSMENT OF MALE PARTNER NEEDS AMONG INFERTILE COUPLES PD29-06: LOWER COGNITIVE FUNCTION IS ASSOCIATED WITH MALE INFERTILITY: AN EXTENDED LOOK PD34-02: UROLOGIST INVOLVEMENT IN SPERM RETRIEVAL PROCEDURES AT AMERICAN INFERTILITY CLINICS MP46-07: INABILITY TO OBTAIN SPERM FOR FRESH IVF CYCLES: ANALYSIS OF INCIDENCE AND OUTCOMES USING A NATIONAL DATABASE MP52-14: FOLLICLE-STIMULATING HORMONE THERAPY AFTER MICROSURGICAL VASOEPIDIDYMOSTOMY MP52-18: PREDNISONE AFTER VASECTOMY REVERSAL MAY IMPROVE SEMEN PARAMETERS Next:Voiding Dysfunction (male)/BPH Voiding Dysfunction (male)/BPH Steven A. Kaplan, MD “This year’s meeting will continue to highlight an association between metabolic factors and the onset of lower urinary tract symptoms secondary to BPH. In addition, data on maturing technologies as well as new investigational methods to treat BPH will be presented,” said Dr. Kaplan, professor of urology at Icahn School of Medicine at Mount Sinai, New York. “Finally, updated data on surgical therapies for BPH will be presented as well.” Dr. Kaplan's meeting picks: 044IC: AUA BPH Guidelines: How to Best Diagnose & How to Most Effectively & Safely Treat 060IC: Understanding The Evidence: New Technologies For Treating BPH & LUTS V02: BPH & Transplantation MP01-01: WATER VS WATER II: AQUABLATION THERAPY FOR BENIGN PROSTATIC HYPERPLASIA MP01-05: THE RESULTS OF ONE ARM MULTICENTER PROSPECTIVE STUDY ON AN INNOVATIVE MINIMALLY INVASIVE SURGICAL TECHNIQUE FOR LUTS MANAGEMENT: THE SECOND GENERATION TEMPORARY IMPLANTABLE NITINOL DEVICE (I-TIND) MEDITATE® MP01-06: EFFECTS OF POLOXAMER-BASED THERMO-SENSITIVE SOL-GEL ON URETHRAL STRICTURE AFTER TRANSURETHRAL RESECTIONS OF THE PROSTATE FOR BENIGN PROSTATIC HYPERPLASIA : A MULTICENTER, SINGLE BLINDED, RANDOMIZED CONTROLLED STUDY MP01-07: PROSTACARE: WATER ELECTROLYSIS SYSTEM FOR THE TREATMENT OF BENIGN PROSTATE HYPERPLASIA MP01-11: LONG-TERM REOPERATION RATES FOLLOWING SURGERY FOR BPH: VARIATION BASED ON SURGICAL MODALITY MP01-19: EFFECT OF INDEX SURGICAL CARE SETTING ON 30-DAY REVISIT RATES AND ASSOCIATED COSTS FOLLOWING OUTLET PROCEDURE FOR SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA PD10-01: THE IMPACT OF TRAINING ERA ON THE OUTCOMES OF TRANSURETHRAL PROSTATECTOMY PD10-07: MULTI-INSTITUTIONAL PROPENSITY MATCHED COMPARISON OF ROBOTIC-ASSISTED SIMPLE PROSTATECTOMY AND THULIUM LASER ENUCLEATION OF THE PROSTATE PD24-05: PROSTATIC ARTERY EMBOLIZATION TO TREAT LOWER URINARY TRACT SYMPTOMS ATTRIBUTABLE TO BENIGN PROSTATIC HYPERPLASIA: A SINGLE CENTER ANALYSIS OF 2-YEAR OUTCOMES MP45-08: PROSTATIC URETHRAL LIFT (PUL) AND MAGNETIC RESONANCE IMAGING (MRI): DEFINING ARTEFACT AND RISK OF OBSCURING SIGNIFICANT CANCER. MP45-16: PHOTOSELECTIVE VAPORIZATION OF THE PROSTATE: FAVOURABILITY OF STUDY RESULTS AS A FUNCTION OF CONFLICTS OF INTEREST AND INDUSTRIAL SPONSORSHIP Next: Female Urology Female Urology Priya Padmanabhan, MD, MPH "Past meetings have had much focus on the implications of mesh complications in female pelvic medicine and reconstructive surgery [FPMRS], robotic apical prolapse repairs, and the role of obesity in incontinence management,” said Dr. Padmanabhan, associate professor of urology at the University of Kansas, Kansas City. “Tertiary OAB treatment is now abuzz with applications in atypical populations, trending of alternative and future options of neuromodulation (ie, implantable tibial nerve stimulation and improved batteries). “Some other hot topics include: gender disparity patterns in FPMRS, the questioning of our practices in screening and prevention of UTIs, the clinical significance of vaginal lasers, and basic research advances in stress urinary incontinence.” Dr. Padmanabhan's meeting picks: 036IC: What the Urologist Needs to Know to Manage Female Sexual Dysfunction 054IC: The Indications for Vaginal Thermotherapy: What is (and is there) a Role for Laser Treatment Journal of Urology: Top Papers: Female Urology and Urodynamics Highlights: Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) Complex Cases: Pelvic Floor Medicine PD06-09: ASSOCIATION OF URINARY LEAKAGE WITH DECREASED TESTOSTERONE IN OLDER WOMEN: RESULTS FROM THE HEALTH, AGING, AND BODY COMPOSITION STUDY PD06-10: SAFETY OF INTRADETRUSOR ONABOTULINUMTOXINA INJECTION IN THE ASYMPTOMATIC PATIENT WITH A POSITIVE URINE DIP PD06-11: INTRAVESICAL BOTULINUM TOXIN A INJECTIONS IN PATIENTS ON ANTIPLATELET AND ANTICOAGULATION THERAPY PD31-02: LONG-TERM RESULTS OF SAFETY, EFFICACY, QUALITY OF LIFE AND SATISFACTION OF PATIENTS TREATED FOR REFRACTORY OAB USING AN IMPLANTABLE TIBIAL NEUROSTIMULATION SYSTEM: RENOVA ISTIM™ SYSTEM PD36-06: THE EFFECT OF SELECTIVE BLADDER DENERVATION IN FEMALE REFRACTORY OVERACTIVE BLADDER WITH OR WITHOUT DETRUSOR OVERACTIVITY PD02-02: URETHRAL SLING TRENDS FOR NEW YORK STATE FROM 2005 TO 2015: FPMRS-TRAINED PHYSICIANS COMPARED TO NON-FELLOWSHIP TRAINED COUNTERPARTS PD31-06: THE IMPACT OF FRAILTY ON THE TREATMENT OF OVERACTIVE BLADDER IN OLDER ADULTS PD61-02: OUTFLOW OBSTRUCTION IS ASSOCIATED WITH (EARLIER) FILLING SENSATION AND DETRUSOR OVERACTIVITY AND (HIGHER) DETRUSOR FILLING PRESSURES IN MAN BUT ALSO IN WOMEN PD65-03: TO STAGE OR NOT TO STAGE? - A COST MINIMIZATION ANALYSIS OF SACRAL NEUROMODULATION PLACEMENT STRATEGIES PD06-02: EFFICACY OF SELF-REPORTED DATABASES PD31-11: ASSOCIATION OF URINARY LEAKAGE FREQUENCY WITH BIOMARKERS OF SYSTEMIC INFLAMMATION: RESULTS FROM THE HEALTH, AGING, AND BODY COMPOSITION STUDY PD65-05: PTNS: STILL GOING STRONG OR AN EVER ENDING STORY? Next:Pediatrics Pediatrics Barry A. Kogan, MD “Reconstructive and robot surgery remain of great interest this year in the presentations. On the other hand, diagnosis and treatment of reflux is of lesser interest, as is (surprisingly) antenatal hydronephrosis,” said Dr. Kogan, chief of urology at Albany, Albany, NY. “The older generation of pediatric urologists keep trying to bury robotic procedures that seem to have few benefits over open surgery, but they keep coming back. [The Crossfire session] should be a great debate. “There is also a session on whose hypospadias repair is better. There is constant evolution in this area, so this should be an informative and fun session,” Dr. Kogan said. Dr. Kogan's meeting picks: 073IC: Common Problems in Pediatric Urology Crossfire: Controversies in Urology: Ureteral Reimplantation should be Robotic Debate: Hypospadias: My Way is Best John Duckett Memorial Lecture: How Urodynamics Influenced Pediatric Urology Next:Late-breaking abstracts Late-breaking abstracts Neal D. Shore, MD Clinical practice, Myrtle Beach, SC LBA-09: DAROLUTAMIDE DELAYS PROSTATE-SPECIFIC ANTIGEN PROGRESSION AND TIME TO NEXT ANTICANCER THERAPIES IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER LBA-10: ARCHES – EFFICACY OF ANDROGEN DEPRIVATION THERAPY WITH ENZALUTAMIDE OR PLACEBO IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER: PROSTATE-SPECIFIC ANTIGEN RESULTS LBA-12: CALGB 90203 (ALLIANCE): RADICAL PROSTATECTOMY WITH OR WITHOUT NEOADJUVANT CHEMOHORMONAL THERAPY IN MEN WITH CLINICALLY LOCALIZED, HIGH RISK PROSTATE CANCER LBA-16: NEPHRON-SPARING MANAGEMENT OF LOW GRADE (LG) UTUC WITH UGN-101 (MITOMYCIN GEL) FOR INSTILLATION: THE OLYMPUS TRIAL EXPERIENCE LBA-18: PRELIMINARY PHASE 2 CLINICAL RESULTS OF IL-15RÎ±FC SUPERAGONIST N-803 WITH BCG IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) PATIENTS DEMONSTRATES 82% CR OF CARCINOMA IN SITU (CIS) LBA-21: 68GA-PSMA-11 PET/CT DETECTS PROSTATE CANCER AT EARLY BIOCHEMICAL RECURRENCE WITH SUPERIOR DETECTION RATE AND READER AGREEMENT WHEN COMPARED TO 18F-FLUCICLOVINE PET/CT IN A PROSPECTIVE HEAD-TO-HEAD COMPARATIVE PHASE 3 STUDY LBA-25: RESIST-PC PHASE 2 TRIAL: 177LU-PSMA-617 RADIONUCLIDE THERAPY FOR METASTATIC CASTRATE-RESISTANT PROSTATE CANCER LBA-26: PIVOTAL TRIAL OF MRI-GUIDED TRANSURETHRAL ULTRASOUND ABLATION IN MEN WITH LOCALIZED PROSTATE CANCER Next:Quality and Patient SafetyQuality and Patient Safety J. Stuart Wolf, Jr., MD "Awareness of the opioid crisis has been growing for several years now. At this AUA annual meeting there will be many presentations on important aspects of the opioid crisis, including the general over-prescription of opioids after urologic surgery, the association of post-surgical opioid prescribing with chronic opioid use, alternatives to post-operative opioids, and the impact of interventions to decrease post-surgical opioid prescribing," said Dr. Wolf, professor of urology at Dell Medical School at The University of Texas, Austin. Dr. Wolf's meeting picks: MP10-10: PATIENT-LEVEL VALIDATION OF PROSTATE CANCER DATA COLLECTED VIA AUTOMATED EXTRACTION FROM STRUCTURED AND UNSTRUCTURED ELECTRONIC HEALTH RECORD (EHR) RECORDS MP10-11: PAIN MANAGEMENT IN OUTPATIENT UROLOGIC PROCEDURES - A PROSPECTIVE RANDOMIZED TRIAL OF OXYCODONE VERSUS KETOROLAC MP15-04: IMPACT OF UROLOGIC SURGERY ON INCREASED RATES OFPERSISTENT OPIOID USE: A NATIONAL SAMPLE PD53-12: INCIDENCE, RISK FACTORS, AND PERIOPERATIVE OUTCOMES ASSOCIATED WITH CLOSTRIDIUM DIFFICILE INFECTION IN UROLOGIC SURGERY: ANALYSIS OF THE AMERICAN COLLEGEOF SURGEONS NATIONAL SURGICAL QUALITY IMPROVEMENT PROJECT DATABASE PD58-01: RECOMMENDATIONS FOR OPIOID PRESCRIBING AFTER MINIMALLY INVASIVE UROLOGICAL SURGERY: A MULTIDISCIPLINARY EXPERT PANEL CONSENSUS PD58-02: OVER USE OF OPIOIDS AFTER PROSTATECTOMY: STATEWIDE EXPERIENCE FROM THE MICHIGAN UROLOGIC SURGERY IMPROVEMENT COLLABORATIVE (MUSIC) PD58-04: EFFECT OF A PROSPECTIVE OPIOID REDUCTION INTERVENTIONON OPIOID PRESCRIBING AND USE AFTER RADICALPROSTATECTOMY: RESULTS OF THE ORIOLES INITIATIVE Next:Clinical EpidemiologyClinical Epidemiology Peter C. Albertsen, MD In surveying the area of epidemiologic trends/socioeconomics, “measuring and describing practice variation is clearly a major theme this year,” said Dr. Albertsen, chief of urology at the University of Connecticut Health Center, Farmington. “As this type of analysis forms the basis for any quality improvement project. The use of electronic medical records and large databases that derive from them become more ubiquitous, these types of studies will become more important. Equally important, urologists need to pay attention to these reports because their own practice patterns may be evaluated and compared against evolving norms.” Dr. Albertsen also highlighted several abstracts that utilized social media for collecting data and evaluating trends. “I suspect this new method of conducting urologic research will increase in the future,” he said. Among other trends to watch for at this year’s meeting, Dr. Albertsen pointed out, are: the growing use of nonphysician providers and telemedicine to address the urologist shortage, the opioid crisis, and the wide variability in acceptance of active surveillance for prostate cancer among community urologists. Dr. Albertsen's meeting picks: MP33-14: AN INVESTIGATION INTO HEALTH RELATED QUALITY OF LIFE OUTCOMES OF LOW-RISK PROSTATE CANCER PATIENTS TREATED WITH ACTIVE SURVEILLANCE VERSUS DEFINITIVE TREATMENT MP39-02: A NOVEL APPROACH TO IDENTIFY DISPARITIES IN ACCESS TO UROLOGIC CARE BASED ON DRIVING TIME MP39-11: PRACTICE LEVEL VARIATION IN THE USE OF IMAGING AFTER SHOCKWAVE LITHOTRIPSY (SWL): DATA FROM A STATEWIDE CLINICAL REGISTRY MP39-12: ENHANCED RECOVERY AFTER SURGERY PROTOCOL FOR URETEROSCOPY: A PROSPECTIVE COMPARATIVE STUDY EVALUATING A NO OPIOID VERSUS STANDARD PROTOCOL MP39-16: SURVEY ON CURRENT PRACTICE IN ANTIBIOTIC PROPHYLAXIS PRIOR TO URETERAL STENT REMOVAL MP44-01: LARGE VARIATION AND LARGE DOSES: OPIOID PRESCRIBING PATTERNS IN A NATIONAL VA COHORT MP44-09: OVERTREATMENT AND UNDERUTILIZATION OF WATCHFUL WAITING IN MEN WITH LIMITED LIFE EXPECTANCY: AN ANALYSIS OF THE MICHIGAN UROLOGICAL SURGERY IMPROVEMENT COLLABORATIVE REGISTRY PD63-07: UNDERSTANDING OF PROGNOSIS IN NON-METASTATIC PROSTATE CANCER: A RANDOMISED COMPARATIVE STUDY OF CLINICIAN ESTIMATES AGAINST THE PREDICT PROSTATE TOOL Next:OAB/Male IncontinenceOAB/Male Incontinence Gopal H. Badlani, MD Professor of urology, Wake Forest Baptist Medical Center, Winston-Salem, NC Dr. Badlani's meeting picks: MP07-01: A BRIEF QUESTIONNAIRE TO ASSESS SYMPTOMS IN NEUROGENIC BLADDER: THE NBSS-SF MP07-06: TELEMEDICINE AND HOME MONITORING OF BLADDER FUNCTION FOR MANAGEMENT OF URINARY TRACT INFECTION IN NEUROGENIC BLADDER & SPINAL CORD INJURY MP07-07: DECLINE IN RATES OF BLADDER AUGMENTATION AND INCONTINENT DIVERSION AFTER INTRODUCTION OF ONABOTULINUM TOXIN A IN PATIENTS WITH NEUROGENIC BLADDER MP07-08: CONTEMPORARY MULTICENTER OUTCOMES OF AUGMENTATION CYSTOPLASTY IN THE ADULT POPULATION OVER A 10-YEAR PERIOD: A NEUROGENIC BLADDER RESEARCH GROUP (NBRG) STUDY MP07-12: THE EFFICACY OF ONABOTULINUMTOXIN A IN PATIENTS WITH PARKINSON’S DISEASE AND NEUROGENIC DETRUSOR OVERACTIVITY MP07-13: SACRAL NEUROMODULATION IN PARKINSON'S DISEASE PATIENTS WITH NEUROGENIC BLADDER MP07-20: STERILE VS CLEAN INTERMITTENT BLADDER CATHETERIZATION: A RANDOMIZED CLINICAL TRIAL IN MYELOMENINGOCELE PATIENTS WITH NEUROGENIC BLADDER PD32-01: LONG-TERM SUCCESS DURABILITY OF TRANSOBTURATOR MALE SLING PD32-09: COMPARISON OF 3.5 CM CUFFS AND TRANSCORPORAL CUFFS IN HIGH-RISK ARTIFICIAL URINARY SPHINCTER POPULATIONS PD37-01: EVALUATION OF COGNITIVE EFFECTS OF ANTIMUSCARINICS: A SYSTEMATIC REVIEW AND META-ANALYSIS PD37-04: ADVANCE XP® FOR THE TREATMENT OF POST-PROSTATECTOMY-INCONTINENCE: 5 YEAR DATA OF A PROSPECTIVE MULTICENTRE STUDY